Role of ST6GAL1 in Thyroid Cancers: Insights from Tissue Analysis and Genomic Datasets

Thyroid cancer is the predominant endocrine-related malignancy. ST6 β-galactoside α2,6-sialyltransferase 1 (ST6GAL1) has been studied in various types of cancers; however, the expression and function of ST6GAL1 in thyroid cancer has not been investigated so far. Previously, we conducted two genome-wide association studies and have identified the association of the ST6GAL1 gene with plasma thyroglobulin (Tg) levels. Since Tg levels are altered in thyroid pathologies, in the current study, we wanted to evaluate the expression of ST6GAL1 in thyroid cancer tissues. We performed an immunohistochemical analysis using human thyroid tissue from 89 patients and analyzed ST6GAL1 protein expression in papillary thyroid cancer (including follicular variant and microcarcinoma) and follicular thyroid cancer in comparison to normal thyroid tissue. Additionally, ST6GAL1 mRNA levels from The Cancer Genome Atlas (TCGA, n = 572) and the Genotype-Tissue Expression (GTEx) project (n = 279) were examined. The immunohistochemical analysis revealed higher ST6GAL1 protein expression in all thyroid tumors compared to normal thyroid tissue. TCGA data revealed increased ST6GAL1 mRNA levels in both primary and metastatic tumors versus controls. Notably, the follicular variant of papillary thyroid cancer exhibited significantly higher ST6GAL1 mRNA levels than classic papillary thyroid cancer. High ST6GAL1 mRNA levels significantly correlated with lymph node metastasis status, clinical stage, and reduced survival rate. ST6GAL1 emerges as a potential cancer-associated glycosyltransferase in thyroid malignancies, offering valuable insights into its diagnostic and prognostic significance.

[1]  C. Hayward,et al.  Genome-Wide Association Analysis and Genomic Prediction of Thyroglobulin Plasma Levels , 2022, International journal of molecular sciences.

[2]  F. Santini,et al.  Molecular Genetics of Follicular-Derived Thyroid Cancer , 2021, Cancers.

[3]  Jihye Hwang,et al.  Regulation of ST6GAL1 sialyltransferase expression in cancer cells. , 2020, Glycobiology.

[4]  D. Skropeta,et al.  Insights into the role of sialylation in cancer progression and metastasis , 2020, British Journal of Cancer.

[5]  M. Daly,et al.  GWAS of thyroid stimulating hormone highlights pleiotropic effects and inverse association with thyroid cancer , 2020, Nature Communications.

[6]  Z. Dai,et al.  Global Burden of Thyroid Cancer From 1990 to 2017 , 2020, JAMA network open.

[7]  L. Kiemeney,et al.  Assessing thyroid cancer risk using polygenic risk scores , 2020, Proceedings of the National Academy of Sciences.

[8]  Yongfu Zhao,et al.  Resveratrol Inhibits the Tumorigenesis of Follicular Thyroid Cancer via ST6GAL2-Regulated Activation of the Hippo Signaling Pathway , 2020, Molecular therapy oncolytics.

[9]  Shixiang Wang,et al.  The UCSCXenaTools R package: a toolkit for accessing genomics data from UCSC Xena platform, from cancer multi-omics to single-cell RNA-seq , 2019, J. Open Source Softw..

[10]  I. Rudan,et al.  Genetic Variants in the ST6GAL1 Gene Are Associated with Thyroglobulin Plasma Level in Healthy Individuals. , 2019, Thyroid : official journal of the American Thyroid Association.

[11]  Huiling He,et al.  Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry. , 2019, Thyroid : official journal of the American Thyroid Association.

[12]  P. Arvan,et al.  The role of thyroglobulin in thyroid hormonogenesis , 2019, Nature Reviews Endocrinology.

[13]  E. Pocheć,et al.  Glycosylation of thyroid-stimulating hormone receptor. , 2019, Endokrynologia Polska.

[14]  M. Prpić,et al.  THYROGLOBULIN AS A TUMOR MARKER IN DIFFERENTIATED THYROID CANCER – CLINICAL CONSIDERATIONS , 2018, Acta clinica Croatica.

[15]  Jeongseon Kim,et al.  Genome-Wide Association Study Reveals Distinct Genetic Susceptibility of Thyroid Nodules From Thyroid Cancer , 2018, The Journal of clinical endocrinology and metabolism.

[16]  V. Galatenko,et al.  Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer , 2018, Glycobiology.

[17]  C. Simillion,et al.  A Cartography of Siglecs and Sialyltransferases in Gynecologic Malignancies: Is There a Road Towards a Sweet Future? , 2018, Front. Oncol..

[18]  Sun Wook Cho,et al.  Genome-wide association and expression quantitative trait loci studies identify multiple susceptibility loci for thyroid cancer , 2017, Nature Communications.

[19]  Yongfu Zhao,et al.  miR-146a and miR-146b promote proliferation, migration and invasion of follicular thyroid carcinoma via inhibition of ST8SIA4 , 2017, Oncotarget.

[20]  Sandya Liyanarachchi,et al.  A genome-wide association study yields five novel thyroid cancer risk loci , 2017, Nature Communications.

[21]  P. Patel,et al.  Glycosylation: a hallmark of cancer? , 2016, Glycoconjugate Journal.

[22]  Y. Sher,et al.  Elevation of β-galactoside α2,6-sialyltransferase 1 in a fructose-responsive manner promotes pancreatic cancer metastasis , 2016, Oncotarget.

[23]  D. McFadden,et al.  Thyroid cancer , 2016, The Lancet.

[24]  J. Fagin,et al.  Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.

[25]  Liping Wang,et al.  ST6Gal-I overexpression facilitates prostate cancer progression via the PI3K/Akt/GSK-3β/β-catenin signaling pathway , 2016, Oncotarget.

[26]  D. Bullard,et al.  The Tumor-Associated Glycosyltransferase ST6Gal-I Regulates Stem Cell Transcription Factors and Confers a Cancer Stem Cell Phenotype. , 2016, Cancer research.

[27]  Yongfu Zhao,et al.  ST6GalNAcII mediates tumor invasion through PI3K/Akt/NF-κB signaling pathway in follicular thyroid carcinoma. , 2016, Oncology reports.

[28]  Giuseppe Opocher,et al.  Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations , 2015, International journal of cancer.

[29]  Michael Rose,et al.  Epigenetic inactivation of ST6GAL1 in human bladder cancer , 2014, BMC Cancer.

[30]  J. Gu,et al.  β-Galactoside α2,6-Sialyltranferase 1 Promotes Transforming Growth Factor-β-mediated Epithelial-Mesenchymal Transition* , 2014, The Journal of Biological Chemistry.

[31]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Papillary Thyroid Carcinoma , 2014, Cell.

[32]  Barbara Jarzab,et al.  Genome-wide association study on differentiated thyroid cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[33]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[34]  Shin-ichiro Takahashi,et al.  Thyroglobulin (Tg) activates MAPK pathway to induce thyroid cell growth in the absence of TSH, insulin and serum. , 2012, Biochemical and biophysical research communications.

[35]  Kari Stefansson,et al.  Discovery of common variants associated with low TSH levels and thyroid cancer risk , 2012, Nature Genetics.

[36]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[37]  B. Caillou,et al.  Wnt/β-Catenin Signaling Pathway Is a Direct Enhancer of Thyroid Transcription Factor-1 in Human Papillary Thyroid Carcinoma Cells , 2011, PloS one.

[38]  S. Bellis,et al.  Sialylation of the Fas Death Receptor by ST6Gal-I Provides Protection against Fas-mediated Apoptosis in Colon Carcinoma Cells* , 2011, The Journal of Biological Chemistry.

[39]  Kari Stefansson,et al.  Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations , 2009, Nature Genetics.

[40]  Peng-Hui Wang,et al.  Altered mRNA expressions of sialyltransferases in ovarian cancers. , 2005, Gynecologic oncology.

[41]  R. Paschke,et al.  Sialylation of Human Thyrotropin Receptor Improves and Prolongs Its Cell-Surface Expression , 2005, Molecular Pharmacology.

[42]  K. Jażdżewski,et al.  Thyroid sialyltransferase mRNA level and activity are increased in Graves' disease. , 2005, Thyroid : official journal of the American Thyroid Association.

[43]  P. Schlag,et al.  Clinical Relevance of Sialyltransferases ST6GAL-I and ST3GAL-III in Gastric Cancer , 2003, Oncology.

[44]  H. Chao,et al.  Enhanced expression of α 2,6-sialyltransferase ST6Gal I in cervical squamous cell carcinoma , 2003 .

[45]  Yuri E Nikiforov,et al.  High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. , 2003, Cancer research.

[46]  K. Czene,et al.  Environmental and heritable causes of cancer among 9.6 million individuals in the Swedish family‐cancer database , 2002, International journal of cancer.

[47]  J. Moskal,et al.  Alpha2,6-sialylation of cell-surface N-glycans inhibits glioma formation in vivo. , 2001, Cancer research.

[48]  F. Pacifico,et al.  Follicular Thyroglobulin (TG) Suppression of Thyroid-restricted Genes Involves the Apical Membrane Asialoglycoprotein Receptor and TG Phosphorylation* , 1999, The Journal of Biological Chemistry.

[49]  L D Kohn,et al.  Autoregulation of thyroid-specific gene transcription by thyroglobulin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Lauro,et al.  A thyroid‐specific nuclear protein essential for tissue‐specific expression of the thyroglobulin promoter. , 1989, The EMBO journal.

[51]  A. de la Chapelle,et al.  Clinical implications of GWAS variants associated with differentiated thyroid cancer. , 2019, Endokrynologia Polska.

[52]  Koichi Suzuki,et al.  Intrinsic regulation of thyroid function by thyroglobulin. , 2014, Thyroid : official journal of the American Thyroid Association.